<DOC>
	<DOCNO>NCT02134964</DOCNO>
	<brief_summary>This study randomize , placebo-controlled , sequential ascending-dose study healthy volunteer administration single multiple dose ( ) investigational drug ( OLT1177 Caps Placebo Caps ) . A total 36 subject enrol across 6 cohort , subject cohort randomize ratio 5 active 1 placebo .</brief_summary>
	<brief_title>Phase 1 Safety PK Study OLT1177 Capsules</brief_title>
	<detailed_description />
	<criteria>Age 18 60 year old , inclusive In good health determine Investigator base subject 's medical history , ECG physical examination Baseline safety laboratory test ( chemistry , hematology , coagulation urinalysis ) Screening Normal blood pressure 130/85 mmHg low Ability provide write , informed consent prior initiation studyrelated procedure , ability , opinion Investigator , comply requirement study Women childbearing potential , men whose sexual partner ( ) woman childbearing potential : 1 . Are intend become pregnant ( include use fertility drug ) study 2 . Are nurse 3 . Are use acceptable , highly effective method contraception followup procedures complete . ( Acceptable , highly effective form contraception define : oral contraception , intrauterine device , systemic [ injectable patch ] contraception , double barrier method , naturally surgically sterile , strict abstinence partner sterilize . If hormonalbased birth control use , subject subject 's sexual partner ( ) must stabledose â‰¥ 3 month prior Baseline visit maintain dose level throughout study . ) Use drug treatment time study ( exception 81 mg aspirin prescription oral systemic contraceptive ) Taking prescription medication ( oral systemic contraceptive ) within 14 day prior administration investigational drug take overthecounter product ( include natural food supplement , vitamin , garlic supplement ) within 14 day prior administration investigational drug , except topical product without systemic absorption Use NSAIDs prescription pain medication , twice week , especially take chronic frequently recur headache Active infection within 3 day Baseline visit History know positive HIV , Hepatitis B surface antigen ( HBsAg ) antibodies Hepatitis C Virus ( HCV ) Diagnosed form internal cancer within past 5 year Any medical condition , diseases prior surgery opinion Investigator would impair subject safely participate trial and/or complete protocol requirement History anaphylactic reaction systemic topical compound Have donate plasma ( 500 mL ) within 7 day prior drug administration Have donate lose whole blood ( exclude volume blood drawn screening procedure study ) prior administration study medication follow : 50 mL 499 mL whole blood within 30 day , 499 mL whole blood within 56 day prior drug administration Is user nicotine product ( include chew tobacco , snuff and/or ecigarettes ) Is willing restrict food beverage include : alcohol , caffeine , poppy seed , xanthine derivative xanthinerelated compound , energy drink , natural health product , grapefruit juice , pomelo , Seville orange marmalade use study specify Section 7.1.5 Is lactose intolerant Is unable unwilling consume product contain bovine byproduct Is unable adhere understand requirement protocol If continuing Part B , subject unable unwilling ingest full studyprovided highfat breakfast within 30 minute Enrollment trial and/or use Investigational Drug device within immediate 30day period prior Baseline visit Enrollment study previously sponsor Olatec Industries LLC , specifically Study OLT117701 , Study OLT117702 Study OLT117703</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Randomized</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>OLT1177</keyword>
	<keyword>Olatec</keyword>
</DOC>